ArticleCase reports in neurology
Acute Fulminant Demyelination after the COVID-19 Vaccine: A Case Report and Review of the Literature.
Article in Case reports in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: COVID-19 vaccination campaigns have successfully limited the spread of the disease and reduced its severity. Neurological side effects of COVID-19 vaccines are rare. To the best of our knowledge, only a few case reports have shown an association between the COVID-19 vaccine and the development of probable acute fulminant demyelination. Case Presentation: In this case report, we investigated and documented a temporal association suggesting a possible causal link between COVID-19 vaccination and acute fulminant demyelination, supported by a review of the existing literature. We describe the case of a 30-year-old female who experienced severe neurological symptoms, including memory loss, disorientation, paranoia, hallucinations, and urinary incontinence, just 3 days after receiving the Pfizer-BioNTech COVID-19 vaccine booster. Magnetic resonance imaging (MRI) revealed multiple T2 lesions with contrast enhancement consistent with demyelination. The condition rapidly progressed to somnolence, disorientation, aphasia, and quadriparesis. Treatment was initiated with pulse intravenous methylprednisolone, plasma exchange, prednisolone, natalizumab, and high-dose cyclophosphamide, resulting in disease stabilization, which was complicated by febrile neutropenia and meningitis. Fortunately, gradual improvement was observed, with MRI showing no new lesions on the follow-up imaging. Conclusion: The literature review revealed limited case reports on COVID-19 vaccine-induced central nervous system demyelination, with no consensus on its link to the Marburg variant of multiple sclerosis. This case highlights the heterogeneity of MS pathogenesis, risk factors, and challenges in managing severe clinical deterioration. Given the rare nature of Marburg MS, early detection and management of the disease lead to a better outcome and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.